查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
RNA治疗的全球市场（~2028）：依产品类型（疫苗/药物）、类型（mRNA/RNA干扰/ASO）和适应症（感染疾病/罕见遗传疾病）
市场调查报告书
商品编码
1350670

RNA治疗的全球市场（~2028）：依产品类型（疫苗/药物）、类型（mRNA/RNA干扰/ASO）和适应症（感染疾病/罕见遗传疾病）

RNA Therapeutics Market by Product (Vaccines, Drugs), Type (mRNA Therapeutics, RNA Interference, Antisense Oligonucleotides), Indication (Infectious Diseases, Rare Genetic Diseases), End User (Hospitals & Clinics) - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 166 Pages | 订单完成后即时交付

价格
简介目录

RNA治疗市场规模预计将从2023年的137亿美元成长到2028年的180亿美元，预测期内年复合成长率为5.6%。

推动整体市场成长的关键要素包括RNA技术製造商和进入者之间的联盟和合作的增加；其中包括类型疗法的用途增加、COVID-19加强疫苗的紧急使用核准和批准激增等等。 siRNA 和环状 RNA (circRNA) 的出现正在扩大治疗范围。

按产品类型划分，疫苗将在 2022 年占据大部分市场份额，而製药部门预测将在预测期内实现最高成长率。该部门的成长是由 RNA 合成和药物输送技术的快速进步所推动的。 FDA 对 RNA 药物的核准增加和管道的强劲增长正在要素该部门的成长。

按类型划分，mRNA 治疗部门在 2022 年占据市场最大份额。基于mRNA的COVID-19疫苗的成功也证明了mRNA技术在开发有效的感染疾病疫苗方面的潜力，增加了人们对mRNA疗法的兴趣和投资。

此外，有迹象表明，罕见遗传疾病部门正在成为一个有前途的部门。罕见遗传疾病的特征通常是患病且治疗模式具有挑战性，这使得基于 RNA 的干预措施的创新潜力令人兴奋。

从地区来看，欧洲预测将在整个预测期内引领市场。欧洲在 RNA 疫苗和 RNA 药物方面的收入份额合计将在 2022 年达到最高，并且预计在预测期内将持续下去。同时，就成长率而言，北美成为预测期内成长最快的地区。

本报告调查了全球RNA治疗市场，并提供了市场概况、市场影响因素和市场机会分析、技术趋势、案例研究、法律制度、市场规模趋势和预测，以及按不同细分市场和地区进行的细分。详细分析、竞争形势、主要企业简介等

目录

第1章简介

第2章调查方法

第3章执行摘要

第4章重要考察

第5章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 技术分析
  • 管道分析
  • 波特五力分析
  • 法规分析
  • 价值链分析
  • 影响客户业务的趋势/干扰
  • 主要利害关係人和采购标准
  • 价格分析
  • 重大会议及活动
  • 生态系市场地图

第6章RNA 治疗市场：依产品类型

  • 疫苗
  • 药品

第7章RNA 治疗市场：依类型

  • mRNA疗法
  • RNA干扰（RNAI）疗法
  • 反义寡核苷酸（ASO）疗法
  • 其他的

第8章RNA 治疗市场：依适应症分类

  • 感染疾病
  • 罕见遗传疾病/遗传性疾病
  • 其他的

第9章RNA 治疗市场：依最终用户分类

  • 医院/诊所
  • 研究环境

第10章RNA治疗市场：按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 其他地区

第11章竞争形势

  • 概述
  • 主要企业的招募策略
  • 市占率分析
  • 主要企业营收占比分析
  • 主要企业企业评价矩阵
  • 新创公司/中小企业的企业评估矩阵
  • 竞争基准化分析
  • 竞争场景/趋势

第12章公司简介

  • 主要企业
    • MODERNA, INC.
    • ALNYLAM PHARMACEUTICALS, INC.
    • NOVARTIS AG
    • IONIS PHARMACEUTICALS, INC.
    • SAREPTA THERAPEUTICS, INC.
    • SANOFI
    • PFIZER INC.
  • 其他公司
    • ARROWHEAD PHARMACEUTICALS, INC.
    • BIONTECH SE
    • ORNA THERAPEUTICS
    • CRISPR THERAPEUTICS
    • SILENCE THERAPEUTICS
    • ASTELLAS PHARMA INC.
    • CUREVAC SE
    • SIRNAOMICS
    • ARCTURUS THERAPEUTICS, INC.
    • ARBUTUS BIOPHARMA

第13章附录

简介目录
Product Code: BT 8784

The RNA therapeutics market is projected to grow from USD 13.7 billion in 2023 to USD 18.0 billion by 2028 at a CAGR of 5.6%. The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics (such as RNA aptamers, siRNA, small-activating RNA), and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (siRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics.

"RNA drugs to witness the highest growth during the forecast period."

Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented the majority of the market share, whereas the RNA drugs segment registered the highest growth rate during the forecast period (2023-2028). The growth of the RNA therapeutics drugs market is propelled by a surge in technological advancements in RNA synthesis and drug delivery. The increasing number of FDA approvals for RNA-based drugs and robust increase in the pipeline are attributive to the segment's lucrative growth. Regulatory approvals of RNA-based drugs, such as Patisiran, Lumasiran, and Viltolarsen, and their successful commercialization have encouraged several therapeutics manufacturers to invest in this space.

"The mRNA therapeutics segment accounted for the largest share in the RNA therapeutics market in 2022."

Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. The mRNA therapeutics segment accounted for the largest share of the RNA therapeutics market in 2022. The success of mRNA-based COVID-19 vaccines has also demonstrated the potential of mRNA technology in developing effective vaccines against infectious diseases, leading to increased interest and investment in mRNA therapeutics. In August 2023, CARsgen Therapeutics Holdings collaborated with Moderna, Inc. to investigate CARsgen's investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna's investigational Claudin18.2 mRNA cancer vaccine.

"Rare genetic/hereditary diseases have emerged as a lucrative segment in the RNA therapeutics market."

Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. Rare genetic diseases, often characterized by their limited prevalence and challenging treatment paradigms, create opportunities for the innovative potential of RNA-based interventions. RNA therapeutics offer a unique avenue to address these rare genetic disorders by precisely targeting the underlying genetic mutations that are responsible for the diseases. Through techniques such as gene silencing using small interfering RNAs (siRNAs) or gene editing using CRISPR/Cas9, RNA therapeutics correct or mitigate the genetic abnormalities causing these conditions.

Europe dominates the global RNA therapeutics market throughout the forecast period.

The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with the highest share of revenue in this segment in 2022. North America has emerged as the fastest-growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs, is highest in 2022, and this is set to continue through the forecast period.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Respondent: Supply Side (70%), Demand side (30%)
  • By Designation: C-level (55%), Director-level (20%), and Others (25%)
  • By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report

  • Moderna, Inc. (US)
  • Alnylam Pharmaceuticals, Inc. (US)
  • Pfizer Inc. (US)
  • Novartis AG (Switzerland)
  • Ionis Pharmaceuticals, Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • Sanofi (France)
  • Arrowhead Pharmaceuticals, Inc. (US)
  • BioNtech SE (Germany)
  • Orna Therapeutics (US)
  • CRISPR Therapeutics (Switzerland)
  • Silence Therapeutics (UK)
  • Astellas Pharma Inc. (Japan)
  • CureVac SE (Germany)
  • Sirnaomics (US)
  • Arcturus Therapeutics Inc. (US)
  • Arbutus Biopharma (US)

Research Coverage

This report studies the RNA therapeutics market based on product, type, indication, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total RNA therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

.

  • Market Drivers: The key factors driving the overall market growth include an increase in the number of collaborations and partnerships among market players as well as RNA technology manufacturers, an increase in applications of different types of RNA therapeutics and the rapid emergency use authorizations and approvals for COVID-19 booster vaccines.
  • Market Penetration: Comprehensive information on RNA therapeutics offered by the top 17-20 players in the market. The report analyzes the RNA therapeutics market by product, type, indication, end user, and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of RNA therapeutics/end users across key geographic regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the gene editing market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the RNA therapeutics market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 RESEARCH LIMITATIONS
  • 1.6 STAKEHOLDERS
    • 1.6.1 RECESSION IMPACT: RNA THERAPEUTICS MARKET

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: RNA THERAPEUTICS MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RNA THERAPEUTICS MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2022
    • FIGURE 4 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2022
    • 2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    • FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • 2.3 MARKET GROWTH RATE PROJECTION
    • FIGURE 6 RNA THERAPEUTICS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
    • FIGURE 7 GROWTH ANALYSIS OF DEMAND SIDE DRIVERS: RNA THERAPEUTICS MARKET
  • 2.4 MARKET ESTIMATION AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS
  • 2.7 IMPACT OF ECONOMIC RECESSION ON RNA THERAPEUTICS MARKET
    • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021-2027 (% GROWTH)
    • TABLE 2 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION)
    • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

    • FIGURE 9 RNA THERAPEUTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 RNA THERAPEUTICS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 RNA THERAPEUTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 13 REGIONAL SNAPSHOT: RNA THERAPEUTICS MARKET

4 PREMIUM INSIGHTS

  • 4.1 RNA THERAPEUTICS MARKET OVERVIEW
    • FIGURE 14 GROWING PARTNERSHIPS AND COLLABORATIONS AMONG KEY PLAYERS TO DRIVE MARKET
  • 4.2 NORTH AMERICA: RNA THERAPEUTICS MARKET SHARE, BY PRODUCT AND COUNTRY (2022)
    • FIGURE 15 VACCINES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA THERAPEUTICS MARKET IN 2022
  • 4.3 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 16 INFECTIOUS DISEASES TO DOMINATE NORTH AMERICAN RNA THERAPEUTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: RNA THERAPEUTICS MARKET
    • TABLE 4 IMPACT ANALYSIS: RNA THERAPEUTICS MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing partnerships and collaborations between market players and RNA technology manufacturers
      • 5.2.1.2 Increasing number of novel modalities for RNA therapeutics
      • 5.2.1.3 Growing number of emergency use authorizations and approvals for COVID-19 booster vaccines
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Discontinuation or recalls of RNA therapeutic products
    • TABLE 5 LIST OF RNA THERAPEUTICS FOR WHICH CLINICAL DEVELOPMENT WAS HALTED
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Higher progress in development of RNA aptamer-based therapeutics
    • TABLE 6 RNA APTAMERS UNDER CLINICAL DEVELOPMENT
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA
  • 5.3 TECHNOLOGY ANALYSIS (RNA VACCINE AND THERAPY MANUFACTURING)
    • 5.3.1 PARAMETERS OF MANUFACTURING
    • 5.3.2 CIRCULAR RNA ENGINEERING
  • 5.4 PIPELINE ANALYSIS
    • FIGURE 18 PIPELINE THERAPIES, BY CATEGORY, 2022
    • 5.4.1 PIPELINE ANALYSIS FOR KEY MARKET PLAYERS (TOP 5)
      • 5.4.1.1 Moderna, Inc.
    • TABLE 7 PIPELINE CANDIDATES OF MODERNA, INC.
      • 5.4.1.2 Pfizer, Inc.
    • TABLE 8 PIPELINE CANDIDATES OF PFIZER INC.
      • 5.4.1.3 Alnylam Pharmaceuticals, Inc.
    • TABLE 9 PIPELINE CANDIDATES OF ALNYLAM PHARMACEUTICALS, INC.
      • 5.4.1.4 Novartis AG
    • TABLE 10 PIPELINE CANDIDATES OF NOVARTIS AG
      • 5.4.1.5 Ionis Pharmaceuticals, Inc.
    • TABLE 11 PIPELINE CANDIDATES OF IONIS PHARMACEUTICALS, INC.
  • 5.5 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 12 PORTER'S FIVE FORCES ANALYSIS: RNA THERAPEUTICS MARKET
    • 5.5.1 THREAT OF NEW ENTRANTS
    • 5.5.2 THREAT OF SUBSTITUTES
    • 5.5.3 BARGAINING POWER OF BUYERS
    • 5.5.4 BARGAINING POWER OF SUPPLIERS
    • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY ANALYSIS
    • TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS OF RNA THERAPEUTICS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.9 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA-BASED THERAPEUTICS
    • 5.9.2 BUYING CRITERIA FOR RNA THERAPEUTIC PRODUCTS/MEDICINES
    • FIGURE 22 KEY BUYING CRITERIA FOR END USERS
  • 5.10 PRICING ANALYSIS
    • 5.10.1 PRICING ANALYSIS FOR FDA-APPROVED RNA THERAPEUTICS, BY PRODUCT
    • TABLE 17 AVERAGE SELLING PRICE FOR RNA VACCINES AND DRUGS, BY REGION
    • 5.10.2 PRICING TREND ANALYSIS: RNA VACCINES AND DRUGS
  • 5.11 KEY CONFERENCES AND EVENTS (2023-2024)
    • TABLE 18 KEY CONFERENCES AND EVENTS IN RNA THERAPEUTICS MARKET (2023-2024)
  • 5.12 ECOSYSTEM MARKET MAP

6 RNA THERAPEUTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 19 RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 VACCINES
    • 6.2.1 INCREASED NUMBER OF APPROVALS AND HIGHER INVESTMENTS FOR COVID-19 BOOSTER VACCINES TO DRIVE MARKET
    • TABLE 20 RNA THERAPEUTICS MARKET FOR VACCINES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 21 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 22 EUROPE: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR VACCINES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.3 DRUGS
    • 6.3.1 GROWING FUNDING AND INVESTMENTS IN RNA THERAPEUTICS RESEARCH TO DRIVE MARKET
    • TABLE 24 RNA THERAPEUTICS MARKET FOR DRUGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 25 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 26 EUROPE: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR DRUGS, BY COUNTRY, 2021-2028 (USD MILLION)

7 RNA THERAPEUTICS MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 28 RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • 7.2 MRNA THERAPEUTICS
    • 7.2.1 INCREASING INVESTMENTS FOR COVID-19 MRNA VACCINES TO DRIVE MARKET
    • TABLE 29 RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 30 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 31 EUROPE: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR MRNA THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.3 RNA INTERFERENCE (RNAI) THERAPEUTICS
    • 7.3.1 INCREASING NUMBER OF APPROVALS FOR SIRNA THERAPEUTICS BY US FDA TO DRIVE MARKET
    • TABLE 33 RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 34 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 35 EUROPE: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 36 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RNA INTERFERENCE (RNAI) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.4 ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS
    • 7.4.1 INCREASED NUMBER OF CHEMICAL MODIFICATIONS AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
    • TABLE 37 RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 39 EUROPE: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR ANTISENSE OLIGONUCLEOTIDE (ASO) THERAPEUTICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 7.5 OTHER THERAPEUTICS

8 RNA THERAPEUTICS MARKET, BY INDICATION

  • 8.1 INTRODUCTION
    • TABLE 41 RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2 INFECTIOUS DISEASES
    • 8.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES AND GROWING INVESTMENTS IN R&D TO DRIVE MARKET
    • TABLE 42 RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 43 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 44 EUROPE: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.3 RARE GENETIC/HEREDITARY DISEASES
    • 8.3.1 TECHNOLOGICAL INNOVATION AND INCREASED DEMAND FOR PERSONALIZED MEDICINES TO DRIVE MARKET
    • TABLE 46 RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 47 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 EUROPE: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RARE GENETIC/HEREDITARY DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 8.4 OTHER INDICATIONS
    • TABLE 50 RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

9 RNA THERAPEUTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 54 RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 HOSPITALS AND CLINICS
    • 9.2.1 INCREASED PREVALENCE OF CHRONIC DISEASES AND HIGHER EFFICACY OF RNA-BASED THERAPIES TO DRIVE MARKET
    • TABLE 55 RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 56 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 57 EUROPE: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2021-2028 (USD MILLION)
  • 9.3 RESEARCH SETTINGS
    • 9.3.1 HIGHER THERAPEUTIC POTENTIAL OF RNA TECHNOLOGY TO CREATE NEW OPPORTUNITIES IN MEDICAL RESEARCH
    • TABLE 59 RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY REGION, 2021-2028 (USD MILLION)
    • TABLE 60 NORTH AMERICA: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 EUROPE: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: RNA THERAPEUTICS MARKET FOR RESEARCH SETTINGS, BY COUNTRY, 2021-2028 (USD MILLION)

10 RNA THERAPEUTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 63 RNA THERAPEUTICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: RNA THERAPEUTICS MARKET SNAPSHOT
    • TABLE 64 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 65 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 66 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 67 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 68 NORTH AMERICA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 Growing technological innovation in RNA delivery systems and rising investments in biopharmaceutical research to drive market
    • TABLE 69 LIST OF RECENT RNA THERAPEUTICS APPROVED BY FDA
    • TABLE 70 US: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 71 US: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 72 US: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 73 US: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Increasing government initiatives and investments for life science research to drive market
    • TABLE 74 CANADA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 75 CANADA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 76 CANADA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 77 CANADA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 78 EUROPE: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 79 EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 80 EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 81 EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 82 EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Rising number of market players and growing public and private funding for research activities to drive market
    • TABLE 83 GERMANY: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 84 GERMANY: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 85 GERMANY: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 86 GERMANY: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Growing pharmaceutical manufacturing industry and increasing number of clinical trials for oncology to drive market
    • TABLE 87 FRANCE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 88 FRANCE: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 89 FRANCE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 90 FRANCE: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 UK
      • 10.3.4.1 Higher R&D investment by pharmaceutical companies for RNA-based drug discovery to drive market
    • TABLE 91 UK: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 92 UK: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 93 UK: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 94 UK: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 REST OF EUROPE
    • TABLE 95 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 96 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 97 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 98 REST OF EUROPE: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: RNA THERAPEUTICS MARKET SNAPSHOT
    • TABLE 99 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 JAPAN
      • 10.4.2.1 Increasing geriatric population and rising government initiatives for drug innovation to drive market
    • TABLE 104 JAPAN: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 105 JAPAN: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 106 JAPAN: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 107 JAPAN: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Low manufacturing costs and increased number of R&D activities to drive market
    • TABLE 108 CHINA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 109 CHINA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 110 CHINA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 111 CHINA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 SOUTH KOREA
      • 10.4.4.1 Increasing number of government initiatives and growing R&D activities for RNA therapeutics to drive market
    • TABLE 112 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 113 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 114 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 115 SOUTH KOREA: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 116 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 117 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 118 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 119 REST OF ASIA PACIFIC: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • TABLE 120 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 121 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 122 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
    • TABLE 123 REST OF THE WORLD: RNA THERAPEUTICS MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS IN RNA THERAPEUTICS MARKET
    • FIGURE 25 KEY PLAYER STRATEGIES IN RNA THERAPEUTICS MARKET, 2021-2023
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 26 MARKET SHARE ANALYSIS OF TOP 3 PLAYERS IN RNA THERAPEUTICS MARKET, 2022
    • TABLE 124 DEGREE OF COMPETITION: RNA THERAPEUTICS MARKET
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 27 REVENUE SHARE ANALYSIS OF TOP 4 PLAYERS IN RNA THERAPEUTICS MARKET, 2020-2022
  • 11.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 28 COMPANY EVALUATION MATRIX FOR KEY PLAYERS: RNA THERAPEUTICS MARKET, 2022
  • 11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 RESPONSIVE COMPANIES
    • FIGURE 29 COMPANY EVALUATION MATRIX FOR START-UPS/SMES: RNA THERAPEUTICS MARKET, 2022
  • 11.7 COMPETITIVE BENCHMARKING
    • TABLE 125 DETAILED LIST OF KEY START-UPS/SMES: RNA THERAPEUTICS MARKET
  • 11.8 COMPETITIVE SCENARIOS AND TRENDS
    • 11.8.1 KEY PRODUCT APPROVALS
    • TABLE 126 KEY PRODUCT APPROVALS, JANUARY 2021-AUGUST 2023
    • 11.8.2 KEY DEALS
    • TABLE 127 KEY DEALS, JANUARY 2021-AUGUST 2023
    • 11.8.3 OTHER KEY DEVELOPMENTS
    • TABLE 128 OTHER KEY DEVELOPMENTS, JANUARY 2021-AUGUST 2023

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 12.1 KEY PLAYERS
    • 12.1.1 MODERNA, INC.
    • TABLE 129 MODERNA, INC.: COMPANY OVERVIEW
    • FIGURE 30 MODERNA, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 ALNYLAM PHARMACEUTICALS, INC.
    • TABLE 130 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 31 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.3 NOVARTIS AG
    • TABLE 131 NOVARTIS AG: COMPANY OVERVIEW
    • FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2022)
    • 12.1.4 IONIS PHARMACEUTICALS, INC.
    • TABLE 132 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
    • FIGURE 33 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.5 SAREPTA THERAPEUTICS, INC.
    • TABLE 133 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
    • FIGURE 34 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.6 SANOFI
    • TABLE 134 SANOFI: COMPANY OVERVIEW
    • FIGURE 35 SANOFI: COMPANY SNAPSHOT (2022)
    • 12.1.7 PFIZER INC.
    • TABLE 135 PFIZER INC.: COMPANY OVERVIEW
    • FIGURE 36 PFIZER INC.: COMPANY SNAPSHOT (2022)
  • 12.2 OTHER PLAYERS
    • 12.2.1 ARROWHEAD PHARMACEUTICALS, INC.
    • 12.2.2 BIONTECH SE
    • 12.2.3 ORNA THERAPEUTICS
    • 12.2.4 CRISPR THERAPEUTICS
    • 12.2.5 SILENCE THERAPEUTICS
    • 12.2.6 ASTELLAS PHARMA INC.
    • 12.2.7 CUREVAC SE
    • 12.2.8 SIRNAOMICS
    • 12.2.9 ARCTURUS THERAPEUTICS, INC.
    • 12.2.10 ARBUTUS BIOPHARMA
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.2 CUSTOMIZATION OPTIONS
  • 13.3 RELATED REPORTS
  • 13.4 AUTHOR DETAILS